Figure 1
From: Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia
Orthogonalised PLS discriminant analysis scores and loadings plot separating prostate cancer patients and controls based on serum and plasma metabolites from MRS and MS, respectively. The loadings are coloured according to the VIP scores. The metabolites are numbered accordingly: 1: decanoylcarnitine (C10); 2: tetradecenoylcarnitine (C14 : 1); 3: octanoylcarnitine (C8); 4: nonanoylcarnitine (C9); 5: arginine; 6: kynurenine; 7: lysophosphatidylcholine acyl (lysoPC a) C16 : 0; 8: lysoPC a C18 : 0; 9: lysoPC a C20 : 4; 10: phosphatidylcholine diacyl (PC aa) C34 : 4; 11: PC aa C38 : 5; 12: PC aa C40 : 4; 13: PC aa C40 : 5; 14: phosphatidylcholine acyl-alkyl (PC ae) C38 : 2; 15: valine; 16: 2-methylglutarate; 17: lipid2; 18: Gln+Glu; 19: glutamate; 20: pyruvate; 21: lysine; 22: dimethylsulfone; 23: histidine; 24: glucose; 25: tyrosine; and 26: phenylalanine.
